Page 103 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 103
Parallel Session: Liver Transplantation (Cont.) Strauss 2
ABSTRACT SIMEPREVIR + SOFOSBUVIR COMBINATION THERAPY
O110 FOR RECURRENT GENOTYPE-1 HEPATITIS C IN LIVER
13:00 - 13:15 TRANSPLANT RECIPIENTS: A REAL-LIFE MULTICENTER
EXPERIENCE
Helen Te, The United States
ABSTRACT OPERATIONAL TOLERANCE CAUSES A LONG LASTING SCIENTIFIC PROGRAMME
O111 ACTIVE IMMUNOREGULATION WITHIN THE GRAFT
13:15 - 13:30 Elmar Jaeckel, Germany
Parallel Session: Viral Hepatitis B & D: Clinical Strauss 3
Chairs:
Jerzy Jaroszewicz, Poland
Cihan Yurdaydin, Turkey
ABSTRACT HBSAG CLEARANCE AFTER ADDITION OF 48 WEEKS
O112 OF PEGIFN IN HBEAG NEGATIVE CHB PATIENTS ON
11:30 - 11:45 NUCLEOS(T)IDE THERAPY WITH UNDETECTABLE
HBV DNA FOR AT LEAST ONE YEAR: FINAL RESULTS
ABSTRACT FROM ANRS-HB06 PEGAN STUDY: MULTICENTER
O113 RANDOMIZED CONTROLLED PHASE III TRIAL
11:45 - 12:00 Marc Bourliere, France
ABSTRACT HLA DPB1 RS9277535 POLYMORPHISM STRONGLY
O114 PREDICTS HBSAG CLEARANCE IN IFN TREATED
12:00 - 12:15 GENOTYPE D HBEAG-NEGATIVE PATIENTS WITH
CHRONIC HEPATITIS B
ABSTRACT Pietro Lampertico, Italy
O115
12:15 - 12:30 SERUM HBV-RNA LEVELS DECLINE SIGNIFICANTLY IN
CHRONIC HEPATITIS B PATIENTS DOSED WITH THE
NUCLEIC-ACID POLYMER REP2139-CA
Louis Jansen, The Netherlands
HIGH ANTIVIRAL ACTIVITY OF THE HBV CORE
INHIBITOR NVR 3-778 IN THE HUMANIZED UPA/SCID
MOUSE MODEL
Klaus Klumpp, The United States
Vienna, Austria • April 22–26, 2015 103
ABSTRACT SIMEPREVIR + SOFOSBUVIR COMBINATION THERAPY
O110 FOR RECURRENT GENOTYPE-1 HEPATITIS C IN LIVER
13:00 - 13:15 TRANSPLANT RECIPIENTS: A REAL-LIFE MULTICENTER
EXPERIENCE
Helen Te, The United States
ABSTRACT OPERATIONAL TOLERANCE CAUSES A LONG LASTING SCIENTIFIC PROGRAMME
O111 ACTIVE IMMUNOREGULATION WITHIN THE GRAFT
13:15 - 13:30 Elmar Jaeckel, Germany
Parallel Session: Viral Hepatitis B & D: Clinical Strauss 3
Chairs:
Jerzy Jaroszewicz, Poland
Cihan Yurdaydin, Turkey
ABSTRACT HBSAG CLEARANCE AFTER ADDITION OF 48 WEEKS
O112 OF PEGIFN IN HBEAG NEGATIVE CHB PATIENTS ON
11:30 - 11:45 NUCLEOS(T)IDE THERAPY WITH UNDETECTABLE
HBV DNA FOR AT LEAST ONE YEAR: FINAL RESULTS
ABSTRACT FROM ANRS-HB06 PEGAN STUDY: MULTICENTER
O113 RANDOMIZED CONTROLLED PHASE III TRIAL
11:45 - 12:00 Marc Bourliere, France
ABSTRACT HLA DPB1 RS9277535 POLYMORPHISM STRONGLY
O114 PREDICTS HBSAG CLEARANCE IN IFN TREATED
12:00 - 12:15 GENOTYPE D HBEAG-NEGATIVE PATIENTS WITH
CHRONIC HEPATITIS B
ABSTRACT Pietro Lampertico, Italy
O115
12:15 - 12:30 SERUM HBV-RNA LEVELS DECLINE SIGNIFICANTLY IN
CHRONIC HEPATITIS B PATIENTS DOSED WITH THE
NUCLEIC-ACID POLYMER REP2139-CA
Louis Jansen, The Netherlands
HIGH ANTIVIRAL ACTIVITY OF THE HBV CORE
INHIBITOR NVR 3-778 IN THE HUMANIZED UPA/SCID
MOUSE MODEL
Klaus Klumpp, The United States
Vienna, Austria • April 22–26, 2015 103
